News

Multiple sclerosis (MS) is a chronic inflammatory disorder that is thought to impact about 2.3 million people around the ...
New advanced imaging technology that detects specific molecules in the brain may find signs of MS lesions months earlier, a ...
TG Therapeutics, Inc.'s BRIUMVI saw Q1 2025 revenue surge 137% YoY. Click to learn about TGTX growth, upcoming trials, and ...
Understanding the risks of cross-sex hormone therapy is important not only for clinicians and patients but also for policymakers, parents, and the broader public. Medicalized gender transition for ...
In people with benign MS, there is a loss of overall brain tissue but other parts of the brain may grow to help compensate ...
Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market insights reveal exciting opportunities. See more.
New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in multiple sclerosis (MS). PRLs are thought to capture a subset of chronic ...
As the authors further wrote, “Multiple sclerosis (MS) is a chronic disabling disease affecting over 2.8 million people worldwide, with a disproportionate impact on young populations.” ...
A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers.
In this observational study, the researchers examined MRI brain scans of runners before the race and then again within 48 hours of completing the grueling 26.2-mile (42.195-km) route.
In a second trial study of this drug, researchers found it slowed brain shrinkage in people with progressive MS. The FDA put ibudilast on a fast track for possible approval once its trials are ...
For adults in midlife, difficulty getting to sleep and waking up too early may accelerate brain atrophy that is associated with dementia. The brain naturally begins to atrophy beginning in one’s 30s ...